ClinicalTrials.gg
CompletedNCT02115100ASAFUpdated Jul 12, 2022

Treatment of Atrial Fibrillation in Patients by Pulmonary Vein Isolation in Combination With Renal Denervation or Pulmonary Vein Isolation Only

An interventional study of procedure in Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation and Out of Range Hypertension, sponsored by Diagram B.V.. Completed at 8 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-12.

Sponsored by Diagram B.V. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Atrial Fibrillation with a site in Spain — 53 open to participants now, 76 under way, 3 of them phase 3. Atrial Fibrillation · Spain.

Enrollment
113th of 162
145 · median 304
Started
2014
with 8 others
No phase
88 of 247
31 open now
Registered
64th of 247
by date

Among the 247 studies in Atrial Fibrillation with a site in Spain, this one is the 113th largest by enrollment of the 162 interventional ones that give a count, is one of 9 that started in 2014, is one of 88 with no phase, and was the 64th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

53 of the 247 studies in Atrial Fibrillation with a site in Spain are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Atrial Fibrillation with a site in Spain, or all of them as a file.
02

Study summary

Prospective, randomized, controlled, multicenter, international clinical trial. The study population consist of patients with paroxysmal or persistent atrial fibrillation with out range hypertension or signs of sympathetic overdrive. Patient will be randomized into one of the following two groups.

group 1 : patients will undergo pulmonary vein isolation, group 2: Patients will undergo pulmonary vein isolation and renal artery denervation.

Read the detailed description

The target group of patients are subjects ages \<65 years, with paroxysmal or persistent atrial fibrillation, who have out of range hypertension (systolic >140 mmHg or >130/80 mmHg in diabetics and patients with chronic renal disease) or signs of sympathetic overdrive. Patients should use at least 2 anti-hypertensive's or should be intolerant for antihypertensive medication.

Atrial fibrillation terminology: If atrial fibrillation recurs more than once but terminates spontaneously within seven days, the term paroxysmal AF is used. This is also used when the episode is less than 48 hours in duration and is terminated with electrical or pharmacological cardioversion. Persistent AF is defined as recurrent AF that is sustained for more than seven days. A patient that is electrically or pharmacologically cardioverted after more than two days is also diagnosed with persistent AF.

After the exclusion of apparent secondary causes of hypertension, patients will be randomized to one of the following interventional treatments:

First arm: PVI (69 patients) Second arm: PVI + RDN (69 patients)

The patient will be treated under conscious sedation or general anesthesia. The control group will consist of patients who undergo PVI alone. The study will be a randomized, controlled trial. The follow up period will be up to one year after the interventional therapy. Patients will be treated clinically and will have regular follow-up at the outpatient clinic of the hospital at which they were treated. If patients receive continuous loop recorders for cardiac rhythm monitoring, this data will be used for the study. The other patients will undergo Holter ECG monitoring at regular intervals during follow-up (at 3, 6 and 12 months after the interventional treatment). During follow-up, the first 3 months after the interventional treatment will be a blanking period, as is common in the ablative therapy of AF (ablations points need to heal, and paroxysms of AF in this period are not associated with therapy failure).

03

Conditions studied

  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation
  • Out of Range Hypertension
  • Signs of Sympathetic Overdrive

Browse trials for

Keywords

  • Paroxysmal atrial fibrillation
  • Persistent atrial fibrillation
  • Out of range hypertension
  • Signs of sympathetic overdrive
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient is willing and able to comply with the protocol and has provided written .
  2. The patient falls within the target group resistant hypertension or sympathetic overdrive
  3. Patient is an acceptable candidate for renal denervation treatment
  4. Patient is \< 65 year of age

Exclusion criteria

Exclusion Criteria:

  1. Documented left atrial diameter on trans thoracic echocardiography (PLAX > 4.5 cm).
  2. to chronic anticoagulation therapy or heparin.
  3. Previous left heart ablation procedure for AF (atrial fibrillation).
  4. Acute coronary syndrome, cardiac surgery, PCI (percutaneous coronary intervention)or stroke within 3 months prior to enrollment.
  5. Untreated hypothyroidism or hyperthyroidism.
  6. More than grade 1/3 valvular regurgitation and/or significant valve stenosis (modest or severe).
  7. (Left ventricular function) \<45% and/or grade 3/4 diastolic dysfunction.
  8. Enrollment in another drug or device study.
  9. Woman currently pregnant or breastfeeding or not using reliable measures during fertile age.
  10. Mental or physical inability to participate in the study.
  11. Planned cardiovascular intervention.
  12. ≤ 12 months.
  13. Renal artery stenosis >50% of the arterial lumen, or renal artery lumen

    ≤3 mm.

  14. Dual or triple ipsilateral renal artery ostia.
  15. Obvious secondary cause of hypertension.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Active comparator
    pulmonary vein+renal artery denervation

    Procedure: pulmonary vein and renal artery denervation

    Procedure: procedure

  • Active comparator
    Pulmonary vein isolation

    Procedure: Pulmonary vein isolation

    Procedure: procedure

Interventions

  • Procedureprocedure

    Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only

    Also known as: Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only

06

What researchers measure

Primary outcomes

  1. Time to first detection of atrial fibrillation > 30 seconds, with the monitoring period starting 3 months after the intervention.

    Time frame: 3 months

Secondary outcomes

  1. A-fib burden during follow-up, expressed in % of the monitoring period, in patients with continuous rhythm monitoring.

    The monitoring starts after 3 months

    Time frame: 12 months

  2. Blood pressure after intervention, and change in blood pressure compared to measurement before the intervention

    Time frame: 3/6/12 months

  3. Blood pressure and heart rate response changes induced by exercise testing

    Time frame: 12 months

  4. Changes in cardiac sympathetic innervation post-intervention compared to measurement before intervention by MIBG in a subset of patients

    Time frame: 12 months

  5. Changes in heart rate variability measures tested by Holter monitoring compared to measurements before the intervention

    Time frame: 12 months

  6. Changes in biomarkers post intervention representing sympathetic tone compared to before the intervention

    Time frame: 12 months

  7. Changes in arterial stiffness measures post intervention ambulatory arterial stiffness index by ambulatory blood pressure monitoring, pulse wave velocity and augmentation index compared to measurement before the intervention

    Time frame: 12 months

07

Study locations

8 sites
  • Isala hospital
    Zwolle, Overijssel 8313AB, Netherlands
  • MUMC
    Maastricht, Netherlands
  • Radboudumc
    Nijmegen, Netherlands
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Hospital Fundación Jimenez Díaz
    Madrid, Spain
  • Hospital Puerta de Hierro
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Virgen de la Victoria
    Malaga, Spain
08

References and documents

Publications

  • Younis A, Steinberg JS. Renal Denervation for Patients With Atrial Fibrillation. Curr Cardiol Rep. 2021 Jul 16;23(9):126. doi: 10.1007/s11886-021-01558-4. PubMed 34269911 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jan 2022, 94 months.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 94 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2014
First posted
Apr 15, 2014
StartActual
Mar 18, 2014
Primary completionActual
Jan 19, 2022
CompletionActual
Jan 19, 2022
Last update
Jul 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02115100
Lead sponsor
Diagram B.V.
Responsible party
Sponsor
First posted
Apr 15, 2014
Start date
Mar 18, 2014
Primary completion
Jan 19, 2022
Completion
Jan 19, 2022
Last update
Jul 12, 2022

Study contacts

Arif Elvan, MD, PhD
principal investigator · Maatschap Cardiologie Isala

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion